PETROSCRAPS.COM

PsiOxus Therapeutics Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102 LONDON–(BUSINESS WIRE)–PsiOxus Therapeutics, Ltd. (PsiOxus) announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated … Read more on Business…. Click Here to Read More

‘HOT TOPICS’ From the Alzheimer’s Association International Conference on Alzheimer’s Disease 2010 – New Alzheimer’s Risk Gene May Affect Memory Scores and Brain Atrophy in Middle Age – Read more on PR Newswire via Yahoo!…. Click Here to Read More